| scholarly article | Q13442814 |
| P2093 | author name string | Alexander R Cobitz | |
| Brendan M Johnson | |||
| Stephen Caltabiano | |||
| Borut Cizman | |||
| Kelly M Mahar | |||
| Olivia Burns | |||
| Bandi Ramanjineyulu | |||
| Gulyeter Serbest | |||
| P2860 | cites work | The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. | Q53233045 |
| Erythropoietin levels in lowlanders and high-altitude natives at 3450 m | Q57104541 | ||
| The effect of chronic renal failure on drug metabolism and transport | Q81742838 | ||
| Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications | Q82667897 | ||
| Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease | Q91470766 | ||
| Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis | Q91470772 | ||
| Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease | Q28235112 | ||
| The physiological and pharmacological roles of cytochrome P450 isoenzymes | Q33597477 | ||
| Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes | Q33985838 | ||
| The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients | Q34403335 | ||
| Peritoneal albumin and protein losses do not predict outcome in peritoneal dialysis patients | Q34857794 | ||
| Anaemia in kidney disease: harnessing hypoxia responses for therapy | Q35836904 | ||
| Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis | Q36006369 | ||
| A randomized trial of intravenous and oral iron in chronic kidney disease | Q36108862 | ||
| Alloimmunization screening after transfusion of red blood cells in a prospective study | Q36283860 | ||
| Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. | Q37042142 | ||
| Regulation of erythropoiesis by hypoxia-inducible factors | Q37063716 | ||
| Abnormal erythropoiesis and the pathophysiology of chronic anemia | Q38190231 | ||
| Investigational therapies for renal disease-induced anemia | Q38819455 | ||
| Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. | Q39291945 | ||
| Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. | Q39810440 | ||
| Red blood cell transfusion use in patients with chronic kidney disease | Q46074645 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P304 | page(s) | 693-701 | |
| P577 | publication date | 2019-02-18 | |
| P1433 | published in | Clinical kidney journal / an academic journal of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) | Q26842221 |
| P1476 | title | Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure | |
| P478 | volume | 12 |
| Q91585394 | A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat | cites work | P2860 |
Search more.